MAIA Biotechnology: Funding, Investors & Team (Sep 2026)
MAIA Biotechnology is a company that focuses on developing and selling targeted therapy and immune-oncology drugs with unique mechanisms of action to improve the lives of cancer patients. Based in Chicago and listed on the NYSE American, MAIA is led by a dedicated management team with extensive drug development experience, dedicated to advancing promising agents to clinical trials. MAIA's business strategy is aimed at creating value for its portfolio of potentially groundbreaking compounds. By diversifying its assets with different compounds that have novel mechanisms of action and potential activity in various types of tumors, MAIA mitigates risks and increases its chances of success. In MAIA's business model, each drug candidate is placed in its own specialized subsidiary company that focuses on research and development. This arrangement allows MAIA to provide focused support to each candidate while sharing resources and management capabilities across subsidiary companies, maintaining an efficient and cost-effective operating structure.
MAIA Biotechnology has raised $60.6M across 11 funding rounds on record, the most recent an undisclosed round of $30.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
MAIA Biotechnology Company Profile and Key Stats
Latest funding round on record: Mar 2026.
MAIA Biotechnology Funding Rounds
MAIA Biotechnology raised $4.0M in an undisclosed round announced in Nov 2023.
4 months later, an undisclosed round of $2.9M was announced in Mar 2024.
7 months later, an undisclosed round of $2.4M was announced in Oct 2024.
2 months later, an undisclosed round of $950k was announced in Dec 2024.
2 months later, an undisclosed round of $2.7M was announced in Feb 2025.
3 months later, an undisclosed round of $700k was announced in May 2025.
7 months later, an undisclosed round of $1.5M was announced in Dec 2025.
3 months later, an undisclosed round of $30.0M was announced in Mar 2026.
MAIA Biotechnology Founders and Leadership Team
Contact details for the MAIA Biotechnology team: 1 of 1 has an email address on file.
Start 14-day free trial →MAIA Biotechnology Funding Compared to Other Biotechnology Startups
MAIA Biotechnology's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like MAIA Biotechnology in Biotechnology and Chicago
Companies Similar to MAIA Biotechnology
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
MAIA Biotechnology Funding FAQs
What does MAIA Biotechnology do?
MAIA Biotechnology is a company that focuses on developing and selling targeted therapy and immune-oncology drugs with unique mechanisms of action to improve the lives of cancer patients. Based in Chicago and listed on the NYSE American, MAIA is led by a dedicated management team with extensive drug development experience, dedicated to advancing promising agents to clinical trials. MAIA's business strategy is aimed at creating value for its portfolio of potentially groundbreaking compounds. By diversifying its assets with different compounds that have novel mechanisms of action and potential activity in various types of tumors, MAIA mitigates risks and increases its chances of success. In MAIA's business model, each drug candidate is placed in its own specialized subsidiary company that focuses on research and development. This arrangement allows MAIA to provide focused support to each candidate while sharing resources and management capabilities across subsidiary companies, maintaining an efficient and cost-effective operating structure.
How much funding has MAIA Biotechnology raised?
MAIA Biotechnology has raised $60.6M across 11 rounds on record. The most recent is an undisclosed round of $30.0M announced in Mar 2026.
When did MAIA Biotechnology last raise funding?
MAIA Biotechnology's most recent funding round on record is an undisclosed round of $30.0M, announced in Mar 2026.
Who founded MAIA Biotechnology?
FundedIQ lists Vlad Vitoc (Founder) at MAIA Biotechnology.
Where is MAIA Biotechnology headquartered?
MAIA Biotechnology is based in Chicago, Illinois, United States.
How many employees does MAIA Biotechnology have?
MAIA Biotechnology is in the 11-50 employee band.
How does MAIA Biotechnology's funding compare to other Biotechnology startups?
MAIA Biotechnology's latest round of $30.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's MAIA Biotechnology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MAIA Biotechnology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.